Adimab
Adimab, LLC is a biotechnology company that provides a yeast-based antibody discovery and engineering platform for biopharma partners.
Founded
2007Adimab, LLC is a biotechnology company that provides a yeast-based antibody discovery and engineering platform for biopharma partners.
Adimab's yeast-based eukaryotic system enables antibody discovery directly in the final IgG and heavy-chain-only formats, which supports developability relative to bacterial or phage display approaches. Its integrated workflow combines high-throughput sorting, real-time screening, and AI-guided engineering to reduce downstream liabilities.
The company reports more than 675 therapeutic programs initiated and over 90 clinical programs advanced by partners. Adimab also offers flexible partnership models and does not compete with partners through an internal pipeline.
Source: adimab.com
Demand for outsourced antibody discovery and multispecific biologics is growing as biopharma companies seek to de-risk early-stage research. Adimab's platform transfer model and non-exclusive technology licenses position it to capture recurring revenue from large pharmaceutical and emerging biotechnology companies.
The expansion of partner programs into late-stage trials and commercial products may increase royalty and milestone income. Continued investment in library diversity, TCR engineering, and computational tools could strengthen its competitive position.
Source: adimab.com
Adimab provides a yeast-based antibody discovery and engineering platform that supports therapeutic programs from target identification through preclinical lead optimization. The platform includes fully human synthetic and immune libraries, AI-guided engineering, and capabilities for IgGs, heavy-chain-only antibodies, multispecifics, and T cell engagers.
Partners can engage through funded discovery, platform transfer, or non-exclusive access to modules such as CD3 and CD28 T cell engagers and heterodimerization technologies. Adimab does not maintain an internal product pipeline, aligning its interests with those of its partners.
Source: adimab.com